Clinical Trial Update: Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment [Phase 2]

View source ↗

Summary

This clinical trial update notes that a Phase 2 study is investigating topical ruxolitinib 1.5% for hidradenitis suppurativa and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Opzelura (ruxolitinib) topical cream (ruxolitinib)

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: RECRUITING